This invention relates to the selective removal of activated T cells using a monovalent
antibody or its
antigen-binding fragment, which includes
heavy chain variable regions and light chain variable regions of an
antibody that specifically binds to CD3. In one embodiment of the present invention, the monovalent anti-CD3
antibody or its
antigen-binding fragment is useful as a
T cell removal agent or
T cell immunosuppressant because it can selectively remove only activated T cells without affecting non-activated T cells. In particular, this invention is useful for the prevention or treatment of
T cell-mediated autoimmune diseases, graft-versus-host diseases, or
organ transplant rejection, as well as for the prevention of graft-versus-
host disease (GVHD) side effects in allogeneic CAR-T
cell therapy.